Skip to main content
Bafna Pharmaceuticals Limited logo

Bafna Pharmaceuticals Limited — Investor Relations & Filings

Ticker · BAFNAPH ISIN · INE878I01022 LEI · 984500D03E2C7Y5EE587 BSE.NS Manufacturing
Filings indexed 247 across all filing types
Latest filing 2025-08-14 Regulatory Filings
Country IN India
Listing BSE.NS BAFNAPH

About Bafna Pharmaceuticals Limited

http://bafnapharma.com/

Bafna Pharmaceuticals Limited specializes in the development, manufacture, and marketing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities certified by WHO-GMP standards, ensuring high-quality production of finished dosage forms including tablets, capsules, syrups, and suspensions. Its therapeutic portfolio spans multiple categories such as anti-infectives, analgesics, cardiovascular, gastrointestinal, and vitamins. The organization serves both domestic and international markets, with a significant presence in emerging regions across Africa, Southeast Asia, and the CIS. In addition to its proprietary product line, the company provides comprehensive contract manufacturing and formulation development services, leveraging its technical expertise and regulatory compliance to meet global healthcare requirements.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings
2025-08-14 English
Change in Management
Board/Management Information Classification · 100% confidence The document is a formal disclosure addressed to stock exchanges (BSE and NSE) pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015. It announces the re-appointment of independent directors and the CEO of Bafna Pharmaceuticals Limited. The content includes detailed profiles of the directors and CEO, terms of appointment, and compliance confirmations. There are no financial statements or performance data, nor is this a report or presentation. The document is an official announcement of changes in the company's board and senior management positions. Therefore, it fits the category of Board/Management Information (MANG). The document length (11,626 characters) supports that it is a full announcement rather than a brief notice or report publication announcement.
2025-08-12 English
Change in Director(s)
Board/Management Information Classification · 100% confidence The document is a formal disclosure addressed to stock exchanges (BSE and NSE) pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015. It announces the re-appointment of two Independent Directors and the Chief Executive Officer of the company, including their terms, profiles, and compliance confirmations. The content focuses on changes in the company's board and senior management positions. There are no financial statements, earnings data, or other report types present. The document is not a report itself but a regulatory announcement about management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length (11626 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2025-08-12 English
Outcome of Board Meeting
Regulatory Filings
2025-08-12 English
Outcome of Board Meeting
Regulatory Filings
2025-08-12 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-08-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.